Do You Have to Go Up a Dose on Mounjaro?

What is Mounjaro's titration schedule, and why does it exist?

Mounjaro is available in six strengths: 2.5, 5, 7.5, 10, 12.5 and 15 mg. Treatment begins at 2.5 mg not because that dose produces significant weight loss on its own, but because starting low gives your system time to adjust before the dose climbs. The KwikPen is pre-filled to last four weeks, so each pen corresponds to roughly one step in the titration pathway. The 2.5 mg pen's job is adjustment; the therapeutic work tends to build from 5 mg upward.

This graduated approach is built into the SmPC (the clinical prescribing document) and reflects what the large-scale SURMOUNT clinical trials found: side effects, which are predominantly gastrointestinal, are most noticeable when the dose changes. Giving the body four weeks at each level before moving up reduces the severity of those effects for most people. A question our prescribers hear most weeks is whether increasing your Mounjaro dose is something you actually have to do, and the honest answer is that the schedule is a starting framework, not a rigid rule.

You can read more about the reasoning behind this structure in our guide to why Mounjaro doses are increased, which covers the clinical and pharmacological background in more detail.

Can your prescriber keep you at the same dose if it's working?

Yes. If a lower dose is producing good weight loss and you are tolerating it well, staying there is entirely legitimate. The goal of treatment is meaningful, sustained weight loss alongside diet and activity changes, not reaching the highest dose on the label. Some people find that 5 mg or 7.5 mg delivers results they are happy with and that side effects are manageable at that level. Moving to a higher dose in that situation is optional.

The Mounjaro SmPC on the Electronic Medicines Compendium sets out that doses are increased based on tolerability. Tolerability, by definition, is personal. A prescriber looking at your four-week progress can weigh up how much weight you have lost, which side effects you have experienced, how they are trending over time, and any relevant medical history before deciding whether moving up makes clinical sense. Staying put is a valid outcome of that conversation.

If you are wondering specifically whether you are allowed to stay at the starting strength, our page on staying on 2.5 mg Mounjaro covers that question directly. The short answer is yes, with prescriber agreement, though it is the exception rather than the rule.

When might a prescriber slow down or skip a dose increase?

Side effects are the most common reason to pause the titration schedule. Nausea, vomiting, diarrhoea and constipation are the effects people most often report, and they tend to spike around dose changes before settling. If those symptoms are still prominent at the end of four weeks, waiting an additional four weeks before the next increase is a reasonable clinical choice and one specifically supported by the prescribing guidance. Rushing upward when side effects have not settled tends to compound them.

Other factors that might lead a prescriber to hold a dose steady include: an acute illness that has affected eating and hydration, a recent medication change that needs monitoring, or simply a patient's personal preference backed by solid progress. There is nothing in the clinical evidence to suggest that slower titration produces worse long-term outcomes; the SURMOUNT-1 trial, published in the New England Journal of Medicine, reported substantial average weight reduction across participants reaching their highest tolerated dose, which was not always 15 mg for everyone.

For a closer look at the timing side of this, our page on when to go up a dose on Mounjaro walks through the typical four-week interval and the signs that might change it.

Does skipping a dose increase affect your results?

Possibly, but the relationship is not simple. Higher doses do, on average, produce greater weight loss in clinical trials, 15 mg produced around 20–21% average body-weight reduction in SURMOUNT-1 compared with lower figures at smaller maintenance doses. That said, individual responses vary considerably, and some people achieve results they are satisfied with well below the maximum. The NHS's tirzepatide medicines page notes that your prescriber will assess whether treatment is still working at whichever dose you are on.

The practical point is that dose decisions should be driven by outcomes and tolerability, not by a desire to reach the highest number. If you are several months into treatment and weight loss has stalled despite good tolerability, that is a conversation worth having with your prescriber about moving up. If weight loss is ongoing and side effects are significant, the same prescriber might reasonably recommend holding steady for longer. Neither scenario has a one-size answer.

You can explore the broader picture of Mounjaro treatment, including how doses fit into the overall programme, on the weight-loss treatments overview. And if the cost of multiple dose strengths is on your mind, our Mounjaro pricing page sets out how private treatment is structured transparently. When you are ready, speak to our prescribers for a free consultation and a clinical view on what dose approach suits your situation.